Skip to main content
Danielle Margalit, MD, Radiation Oncology, Boston, MA

Danielle N. Margalit MD

Head & Neck


Associate Professor of Radiation Oncology, Harvard Medical School Staff Physician, Dana-Farber Cancer Institute and Brigham and Women's Hospital

Join to View Full Profile
  • 450 Brookline AveBoston, MA 02215

  • Phone+1 617-632-3591

Dr. Margalit is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2007 - 2011
  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2006 - 2010
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2007
  • Harvard Medical School
    Harvard Medical SchoolClass of 2006

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2008 - 2026
  • ME State Medical License
    ME State Medical License 2020 - 2025
  • Radiation Oncology
    American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal Cancer
    Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal CancerApril 1st, 2025
  • Trial “Informs Practice Tremendously” for Low-Risk HPV-Oropharyngeal Cancer
    Trial “Informs Practice Tremendously” for Low-Risk HPV-Oropharyngeal CancerOctober 8th, 2024
  • Standard Chemoradiation Remains Superior for HPV-Associated Oropharyngeal Cancer
    Standard Chemoradiation Remains Superior for HPV-Associated Oropharyngeal CancerOctober 4th, 2024
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: